United Kingdom Archives

News and Trends 27 May 2015

NewCo, the union of Sorin and Cyberonics

[UPDATE 27/05/2015]: Sorin’ shareholders approved the merger with Cyberonics in an Extraordinary Meeting. Sorin and Cyberonics, agreed on a merger plan to create a new global leader in medical technologies with a combined equity value of approximately €2.4Bn based on the closing price of Sorin and Cyberonics shares of 25th February. Sorin and Cyberonics will combine […]

May 27, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 27 May 2015

Amgen dumps suicidal-related AstraZeneca’s psoriasis project

AstraZeneca might be facing a public crisis after its partner, Amgen, decided to abandon their common project on psoriasis. The Americans made a getaway from the collaboration after patients treated with brodalumab not only reported to have suicidal ideation, but even committed suicide… AstraZeneca and Amgen’s partnership started back in 2012, as both companies resolved to jointly […]

May 27, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 21 May 2015

The most effective Test for Ovarian Cancer raised €7.4M

Cancer is a devastating disease and, despite all the best efforts to develop new personalized medicines, too many lives end every year because of it. However, this trend might be about to change, after the latest study from University College London, published in the Journal of Clinical Oncology last week. The study highlighted that ROCA, […]

May 21, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 19 May 2015

PsiOxus raised €34.7 Million from First-Class investors

PsiOxus Therapeutics has closed a Series C financing round of €34.7M (£25 million) to progress its lead clinical candidate, enadenotucirev, and a pipeline of follow-on oncolytic programmes. Neil Woodford’s fund, GlaxoSmithKline’s VC unit and Imperial Innovations from Imperial College of London, amongst others, are behind the financing. PsiOxus’ lead product, enadenotucirev, is an oncolytic virus that, […]

May 19, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 18 May 2015

ZuvaSyntha, a new player in the Industrial Biotech field

UK-based BioSyntha Technology and American ZuvaChem have merged and become ZuvaSyntha, an aspiring new player in the industrial biotechnology field. The new company will focus its resources to commercialize the microbial production of industrial chemicals from inexpensive renewable feedstocks, such as syngas and methanol. ZuvaSyntha, will be based in the UK and will be led […]

May 18, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 18 May 2015

Allergist Circassia grabs a couple of Asthma-Specialist companies

The allergy specialist Circassia will acquire two asthma-expert companies: Aerocrine and Prosonix. The British company, which performed the biggest of the fifteen European biotech IPOs in 2014, intends to become a self-sustaining biopharma by focusing on allergies and asthma. The purchases will optimize the launch of CAT-Spire, which represents Circassia’s first drug of a new […]

May 18, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 May 2015

European companies present their cancer treatment solutions in the USA

Each year, the American Society of Clinical Oncology gathers the cancer therapy developers during five days to present their latest results. Roche seems to be the European winner of this roundup, with amazing results of alectinib in non-small cell lung cancer (NSCLC). Roche’s investigational medicine alectinib shrank tumors in nearly half of patients suffering from this […]

May 15, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 13 May 2015

Axovant banks on GSK’s scrapped project

Last December, Axovant acquired for €4.5M ($5 million) the drug candidate SB742457 from GlaxoSmithKline. Four months later, the company announced its initial public offering to raise up to €154M ($173 million). Why is this newly funded company betting on the leftovers of the Big Pharma? The drug candidate SB742457 is a selective 5-HT6 receptor antagonist, developed as an oral […]

May 13, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 13 May 2015

[UPDATE] Adaptimmune raised €156.7M in its IPO

Oxford-based Adaptimmune has launched its IPO on NASDAQ, where the immunotherapist plans to raise about €156.7M. The company is focused on novel cancer immunotherapy products based on T-cell receptors. [UPDATE]: The company successfully raised the quantity expected. Adaptimmune is focused on the use of T-cell therapy to treat cancer. It aims to utilise the body’s own machinery, T […]

May 13, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 11 May 2015

PhoreMost awarded €1.96M to target the “undruggable” Cancer Genes

Cambridge-based PhoreMost has been selected to receive a funding award of €1.96M (£1.4 million) from the UK’s innovation agency, Innovate UK, to develop its lead oncology programme targeting mutant KRAS cancers. The British company that aims to provide low-priced and more diversed therapeutics, has developed ‘Site-Seeker’, a next-generation phenotypic screening platform based on PhoreMost’s Protein […]

May 11, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 10 May 2015

Succesful Phase III for Indivior’s Schizophrenia treatment

Indivior obtained top-line results from its phase III clinical trial of RBP-7000, a candidate treatment for schizophrenia. Based on these successful outcomes, the company expects to submit a New Drug Application to the U.S. FDA for potential approval in 2017. Schizophrenia is a chronic, severe and disabling brain disorder that affects an estimated 26 million […]

May 10, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 8 May 2015

GSK sparks off the Gene Therapy resurgence

GlaxoSmithKline has become the first big pharma company to file a gene therapy approval case to the European Medicines Agency (EMA). The therapy, developed in collaboration with San Raffaele Hospital and the Telethon Foundation in Italy, is designed to cure a disease called adenosine deaminase (ADA) deficiency, which causes severe combined immunodeficiency syndrome, lead to serious infections and, ultimately, death. ADA […]

May 8, 2015 - 4 minutesmins - By Joachim Eeckhout

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

United Kingdom

NewCo, the union of Sorin and Cyberonics

Amgen dumps suicidal-related AstraZeneca’s psoriasis project

The most effective Test for Ovarian Cancer raised €7.4M

PsiOxus raised €34.7 Million from First-Class investors

ZuvaSyntha, a new player in the Industrial Biotech field

Allergist Circassia grabs a couple of Asthma-Specialist companies

European companies present their cancer treatment solutions in the USA

Axovant banks on GSK’s scrapped project

[UPDATE] Adaptimmune raised €156.7M in its IPO

PhoreMost awarded €1.96M to target the “undruggable” Cancer Genes

Succesful Phase III for Indivior’s Schizophrenia treatment

GSK sparks off the Gene Therapy resurgence

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!